Specialty Pharmacy

Atazanavir (Reytaz) is indicated to treat patients with an HIV-1 infection.

Drinking 4 or more cups of coffee per day slashed the risk of colorectal cancer-related mortality in half.

Conflicting breast cancer treatment guidelines can leave many decisions to the discretion of the provider.

Investigational JAK1-selective inhibitor may reduce the symptoms of atopic dermatitis.

Top news of the day from across the health care landscape.

Sofosbuvir/velpatasvir is the first direct acting antiviral therapy registered for use against all 6 genotypes of hepatitis C.

Cisplatin and platinum-based chemotherapies cause hearing loss in up to 80% of adults and more than 50% of children.

Jon Gavras, MD, chief medical officer at Prime Therapeutics, analyzes the benefits of pharmacy benefit tools for patients with private and public insurance.

Unapproved stem cell therapies may cause patient harm with serious and life-threatening diseases.

Infectious disease and HIV specialists may be more willing to prescribe HIV preexposure prophylaxis than primary care providers.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Despite the benefits of oral oncolytics, high out-of-pocket costs could put treatment out of reach for patients with cancer.

A small number of liquid biopsy test results from different providers matched for overlapping genetic sequences.

Treatment with upadacitinib resulted in reduced disease activity and clinical remission in patients with rheumatoid arthritis.

Providing information about breast cancer surgery via an online tool may help patients feel more informed about their treatment options.

Top news of the day from across the health care landscape.

Promacta is a bone marrow stimulant previously approved by the FDA to treat adults and children with chronic immune thrombocytopenia.

A new report highlights the potential pitfalls of formulary exclusion lists used by pharmacy benefit managers.

Daratumumab combination therapy tripled the minimal residual disease negativity rate among patients with multiple myeloma.

The Maraba virus was observed to kill latently infected HIV cells.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses how patient data can be used to drive down drug costs.

Top news of the day from across the health care landscape.

The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.

Oral regimen of ledipasvir and sofosbuvir for hepatitis C virus shows improved treatment outcomes.

With new specialty pharmacies emerging and existing pharmacies evolving, accreditation has become more important.

Taurine may increase the remyelination effects of multiple sclerosis treatments.

Physically fit patients with coronary artery disease were nearly half as likely to die from cancer.